Clinical Trial Update: A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ASP0367 in participants with primary mitochondrial myopathy was terminated, and results have been posted (results posted 2025-06-17).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Myopathy

Drugs mentioned

• ASP0367

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Primary Mitochondrial Myopathy | Phase 2 | Status: TERMINATED | Results posted: 2025-06-17